Marantz Jing L., acting as Chief Medical Officer of Scholar Rock Holding Corp (NASDAQ: SRRK), conducted a sale of 5,798 common shares on January 16, 2026. Executed at an average price of $44.4777 per share, the trade totaled approximately $257,881 in value.
Subsequent to this trade, Jing's direct ownership in Scholar Rock comprises 95,687 shares, a portfolio composed of 24,974 common shares alongside 70,713 restricted stock units (RSUs). This sale was undertaken explicitly to address the tax withholding liabilities arising from RSU vesting that occurred on January 15, 2026. The RSU awards themselves trace back to a grant dated February 12, 2024.
Parallel to this insider transaction, Scholar Rock has been the subject of notable analyst activity and company disclosures. UBS recently initiated coverage on Scholar Rock, assigning a Buy rating with a $60 price target, primarily on the optimistic potential of apitegromab, the company's leading therapeutic candidate.
Similarly, Cantor Fitzgerald maintained an Overweight rating on the stock, underscoring confidence in apitegromab's prospects for regulatory approval as a treatment for spinal muscular atrophy. The company reported that Catalent Indiana, its manufacturing partner, received a warning letter from the U.S. Food and Drug Administration (FDA). Despite this regulatory hurdle, Scholar Rock has affirmed plans to resubmit its biologics license application for apitegromab, targeting a U.S. launch in 2026 contingent upon approval.
Additional analyst perspectives include Wolfe Research's initiation with an Outperform rating and a $42 price target, even after the FDA issued a Complete Response Letter for apitegromab. BMO Capital has adjusted its price target upward to $50 from $45 while maintaining an Outperform rating. This reflects anticipation of accelerated technology transfer efforts to a secondary manufacturing site as a strategic backup.
These developments demonstrate a blend of cautious optimism and proactive strategic planning as Scholar Rock continues to address regulatory challenges and push forward in its drug development pipeline.